COVID-19 Therapeutic Considerations for Children and Pregnant Women
Watch this webinar to learn about tools & processes to help tailor COVID-19 therapies for special populations, including children and pregnant women
Tag: 感染症
COVID-19の治療薬開発を加速
This webinar will explain lessons learned from preparing for and responding to viral outbreaks such as H5N1 and pH1N1 influenza and discuss how insights from model-informed drug development approaches can spur access to medicines for patients.
Using Modeling and Simulation to Optimize the Timing of Maternal Influenza Vaccination
A M&S model was built to offer an alternate approach to dedicated timing studies to determine the best time to vaccinate pregnant women.
Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
Certara 2019年のベストブログ
A selection of short essays from our blog, written to empower our clients with modeling and simulation (M&S), regulatory science, and real-world value assessment solutions to help them solve the toughest drug development problems. In the Best of the Blog, Certara’s scientists and regulatory experts share their learnings, technological advances, and thought leadership.
Supporting Efficient Infectious Disease Drug Development and Commercialization
Certara uses a unique set of disciplines and technologies to address the challenges that infectious disease drug programs face.
Certara Scientists Support TB Alliance’s Groundbreaking New Drug
Certara participated in the pretomanid development program providing scientific support to the TB Alliance and the Bill & Melinda Gates Foundation.
